Company intelligence / Profile preview

Neuracle Genetics

Seoul, Seoul, South Koreaneuraclegenetics.com ↗

Ownership: Private
Development stage: Other

Overview

Neuracle Genetics is developing AAV-based gene therapy products, with programs currently in discovery phase. Their pipeline includes NG-201 for Alzheimer Disease and NG-101 for wet age-related macular degeneration.

Therapeutic areas: OphthalmologyNeurology
Modalities: AAV-based gene therapy
Industry: Biotech

Partnerships

Reyonpharm (for NG-101)

Beyond the preview

Go deeper on Neuracle Genetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuracle Genetics.